These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20304628)

  • 1. Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
    Mackay HJ; Hirte H; Colgan T; Covens A; MacAlpine K; Grenci P; Wang L; Mason J; Pham PA; Tsao MS; Pan J; Zwiebel J; Oza AM
    Eur J Cancer; 2010 Jun; 46(9):1573-9. PubMed ID: 20304628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Dizon DS; Blessing JA; Penson RT; Drake RD; Walker JL; Johnston CM; Disilvestro PA; Fader AN
    Gynecol Oncol; 2012 May; 125(2):367-71. PubMed ID: 22366594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study.
    O'Connor OA; Horwitz S; Masszi T; Van Hoof A; Brown P; Doorduijn J; Hess G; Jurczak W; Knoblauch P; Chawla S; Bhat G; Choi MR; Walewski J; Savage K; Foss F; Allen LF; Shustov A
    J Clin Oncol; 2015 Aug; 33(23):2492-9. PubMed ID: 26101246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer.
    Dizon DS; Damstrup L; Finkler NJ; Lassen U; Celano P; Glasspool R; Crowley E; Lichenstein HS; Knoblach P; Penson RT
    Int J Gynecol Cancer; 2012 Jul; 22(6):979-86. PubMed ID: 22694911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours.
    Lassen U; Molife LR; Sorensen M; Engelholm SA; Vidal L; Sinha R; Penson RT; Buhl-Jensen P; Crowley E; Tjornelund J; Knoblauch P; de Bono JS
    Br J Cancer; 2010 Jun; 103(1):12-7. PubMed ID: 20588278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
    Hainsworth JD; Daugaard G; Lesimple T; Hübner G; Greco FA; Stahl MJ; Büschenfelde CM; Allouache D; Penel N; Knoblauch P; Fizazi KS
    Cancer; 2015 May; 121(10):1654-61. PubMed ID: 25611313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors.
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Rasmussen A; Ooi CE; Buhl-Jensen P; Brown R; Evans TR; DeBono JS
    Clin Cancer Res; 2008 Feb; 14(3):804-10. PubMed ID: 18245542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101).
    Steele NL; Plumb JA; Vidal L; Tjørnelund J; Knoblauch P; Buhl-Jensen P; Molife R; Brown R; de Bono JS; Evans TR
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1273-9. PubMed ID: 20706839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study.
    Kirschbaum MH; Foon KA; Frankel P; Ruel C; Pulone B; Tuscano JM; Newman EM
    Leuk Lymphoma; 2014 Oct; 55(10):2301-4. PubMed ID: 24369094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.
    Giaccone G; Rajan A; Berman A; Kelly RJ; Szabo E; Lopez-Chavez A; Trepel J; Lee MJ; Cao L; Espinoza-Delgado I; Spittler J; Loehrer PJ
    J Clin Oncol; 2011 May; 29(15):2052-9. PubMed ID: 21502553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.
    Takebe N; Beumer JH; Kummar S; Kiesel BF; Dowlati A; O'Sullivan Coyne G; Piekarz R; Rubinstein L; Fogli LK; Vaishampayan U; Goel S; O'Bryant CL; El-Rayes BF; Chung V; Lenz HJ; Kim R; Belani CP; Tuscano JM; Schelman W; Moore N; Doroshow JH; Chen AP
    Br J Clin Pharmacol; 2019 Nov; 85(11):2499-2511. PubMed ID: 31271459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the effect of belinostat in solid tumors by H4 acetylation.
    Marquard L; Petersen KD; Persson M; Hoff KD; Jensen PB; Sehested M
    APMIS; 2008 May; 116(5):382-92. PubMed ID: 18452428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.
    Campbell P; Thomas CM
    J Oncol Pharm Pract; 2017 Mar; 23(2):143-147. PubMed ID: 26921086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer.
    Dovzhanskiy DI; Arnold SM; Hackert T; Oehme I; Witt O; Felix K; Giese N; Werner J
    BMC Cancer; 2012 Jun; 12():226. PubMed ID: 22681698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
    Modesitt SC; Sill M; Hoffman JS; Bender DP;
    Gynecol Oncol; 2008 May; 109(2):182-6. PubMed ID: 18295319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of platinum drug resistance by the histone deacetylase inhibitor belinostat.
    To KK; Tong WS; Fu LW
    Lung Cancer; 2017 Jan; 103():58-65. PubMed ID: 28024697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.
    Luu T; Frankel P; Beumer JH; Lim D; Cristea M; Appleman LJ; Lenz HJ; Gandara DR; Kiesel BF; Piekarz RL; Newman EM
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1201-1208. PubMed ID: 31522242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
    Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
    Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.